The short answer
SELECT enrolled 17,604 participants with overweight or obesity and established cardiovascular disease but without diabetes, testing semaglutide against placebo on major adverse cardiovascular events. Lincoff and colleagues published it in the New England Journal of Medicine in December 2023.
Key facts
- Enrolment
- 17,604
- Population
- Obesity + established CV disease, no diabetes
- Endpoint
- Major adverse cardiovascular events
- Published
- NEJM 2023 (PMID 37952131)
- Weight analysis
- Ryan 2024, Nat Med (PMID 38740993)
- Significance
- Outcome benefit outside diabetes
Why excluding diabetes was the whole design
Cardiovascular outcome trials of diabetes drugs had already shown benefit, but in people with diabetes any cardiovascular effect could plausibly be explained by better glucose control. Removing diabetes from the population removes that explanation. Whatever SELECT found could not be attributed to glycaemic improvement, because the participants were not hyperglycaemic to begin with.
Why the size was necessary
Counting heart attacks, strokes and cardiovascular deaths requires enough events to distinguish a real difference from noise, and those events are relatively rare even in a high-risk population. 17,604 participants followed for years is what it takes. That scale is why outcome trials cost what they do and why most compounds never get one.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it established for the category
That the benefit extends beyond glucose and beyond weight as a number. A drug demonstrating reduced cardiovascular events in people without diabetes is being assessed as a cardiovascular agent, which is a different regulatory and clinical proposition from a weight-management product.
The question it left open
How much of the effect ran through weight reduction and how much through other mechanisms. Ryan and colleagues examined the long-term weight outcomes in SELECT separately in Nature Medicine in 2024. Weight and cardiovascular benefit travel together in the same participants, so attribution remains difficult.
Why it sits beside FLOW and ESSENCE
Three large trials, three organ systems, one compound: cardiovascular events in SELECT, kidney events in FLOW, liver histology in ESSENCE. Read together they describe a metabolic agent rather than an appetite suppressant, and that reframing is the most consequential thing to have happened to this drug class since the weight results themselves.
And what it says about research material
Nothing. SELECT studied a licensed medicine in 17,604 patients under clinical supervision with ethics approval and event adjudication. No research compound is covered by those findings or is an alternative to a prescribed cardiovascular treatment.
Quick reference
| Trial | Organ system | Enrolment | Endpoint type |
|---|---|---|---|
| SELECT | Cardiovascular | 17,604 | Clinical events |
| FLOW | Kidney | 3,533 | Clinical events |
| ESSENCE | Liver | 1,205 | Histological surrogate |
Frequently asked questions
Why did SELECT exclude people with diabetes?
So any cardiovascular benefit could not be attributed to improved glucose control. The participants were not hyperglycaemic to begin with.
Why did it need 17,604 participants?
Cardiovascular events are relatively rare even in high-risk populations, and detecting a real difference requires enough of them.
Was the benefit caused by weight loss?
Not separable. Weight reduction and cardiovascular benefit occurred in the same participants, so attribution remains difficult.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLincoff AM et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023 (PMID 37952131)pubmed.ncbi.nlm.nih.gov
- PubMedRyan DH et al., Long-term weight loss effects of semaglutide in obesity without diabetes in SELECT. Nat Med 2024 (PMID 38740993)pubmed.ncbi.nlm.nih.gov
- PubMedPerkovic V et al., FLOW. NEJM 2024 (PMID 38785209)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Attribution Problem Running Through Every IndicationHeart, kidney and liver benefits all appear alongside substantial weight reduction. Separating the two is harder than it looks, and mostly has not been done.
- Why Biopsy Endpoints Make Liver Trials HardMASH trials score liver biopsies for inflammation and fibrosis. A pathologist's judgement is a noisier endpoint than a number from a machine.
- STEP UP: Testing Whether More Dose Means More EffectA phase 3b trial of once-weekly semaglutide 7.2 mg in 1,407 adults. Why raising the dose is not a trivial question and what a ceiling would mean.
- How a Molecule Lasts a Month Instead of a WeekWeekly dosing comes from albumin binding. Monthly dosing needs something else - an antibody, and the recycling receptor that keeps it in circulation.
- Blocking and Activating the Same Receptor, in One ModelTirzepatide activates GIPR; MariTide blocks it. Both work. A February 2026 mouse study finally compared the two directions under matched conditions.